AOL Money & Finance

HealthCareStocks posts

Feed

Reconciliation is a nasty word for healthcare stocks (UNH, WLP and HUM)

Unless you've been spending your summer vacation on a tropical beach with no television or internet access, you have seen that the public reception to Congress' proposals for heathcare reform have not exactly been well accepted. I mean, nut jobs showing up to town hall meetings with guns strapped to their legs isn't really the norm.

So you would think that the Republicans who are against a public insurance plan are in control, right? Not so fast.

Congressional Democrats are now talking about splitting the healthcare bills into two parts so they can take advantage of a loophole called reconciliation.

Continue reading Reconciliation is a nasty word for healthcare stocks (UNH, WLP and HUM)

Johnson & Johnson (JNJ): A triple A play

"Johnson & Johnson (NYSE: JNJ) has vast holdings, but its strategy is simple: Support a deep pipeline of new drugs and medical devices with an aggressive acquisition strategy and cost controls," notes blue chip investor Richard Moroney.

In his Dow Theory Forecasts, he adds, "And despite the recession, J&J has kept its financial footing, remaining one of the few companies with the top credit rating of AAA." Here's his long term outlook.

"This year the U.S. pharmaceutical market is expected to contract for the first time in 50 years as fewer people visit doctors or start new therapies for chronic conditions.

"Beyond 2009, an economic recovery should reinvigorate J&J, though it is too early to determine whether health-care reform will help or harm the company.

Continue reading Johnson & Johnson (JNJ): A triple A play

Biotech ETFs: Best bets on health care reform

"Health care reform could mean opportunities for astute investors," says Brandon Clay in his Invest With an Edge.

Here, eyes two biotech ETFs that "should be on everyone's watch list." The advisor notes, "With health care on the front burner in Washington, these biotechnology ETFs may finally be ready to pop."

"Investors in health care should think outside the realm of traditional pharmaceutical companies and health insurers. Those sectors are each facing headwinds that make stock picking difficult.

"In addition, several big pharma companiesare desperate to reload their empty pipelines in the face of increased competition from generic drug makers.

Continue reading Biotech ETFs: Best bets on health care reform

MannKind: Speculation on inhaled insulin

"In looking for a highly speculative stock for our portfolio, I have settled on MannKind Corp. (NASDAQ: MNKD), a company that is developing an inhaled insulin product," says Nate Pile.

In his growth-oriented Nate's Notes, the advisor cautions, "I believe we are looking at a situation in which we will either lose most of our money, or triple (or better) our investment in a fairly short period of time."

"In a nutshell, the company's near-term fate hinges upon AFRESA, a novel, ultra rapid acting mealtime insulin therapy being studied for use in adult patients with type 1 and type 2 diabetes mellitus for the treatment of hyperglycemia.

"Working against the company is the fact that there has never been an inhaled insulin product approved for commercial use that has worked very well.

Continue reading MannKind: Speculation on inhaled insulin

Celgene (CELG): Play offense and defense with biotech

"Biotech company Celgene Corp. (NASDAQ: CELG) is a prime example of a stock that plays both offense and defense," says Ian Wyatt.

In his Top Stock Insights, he explains, "The valuation is low and growth is attractive. With the pipeline of products in development, Celegene offers investors a huge upside potential."

"Celgene offers investors a steady product base, a variety of drug treatments in development and a cash pile ready to purchase existing technologies.

"Celgene engages in the discovery of therapies designed to treat cancer and immune-inflammatory related diseases. They have a number of products at the commercial stage.

Continue reading Celgene (CELG): Play offense and defense with biotech

Dr. Reddy's (RDY): Get ready for generic gains

"India-based Dr. Reddy's Laboratories (NYSE: RDY), a generic-drugs play with solid market positions in India, Russia, the US and Germany," says Asian stock expert Yiannis Mostrous.

In his specialty newsletter, The Silk Road Investor, he explains why he has chosen the firm as his latest "Stock of the month".

"Seventy percent of the firm's growth comes from generic drugs, and the trend there has been favorable. New products, market share gains and a revamp of the supply chain in India should contribute to profitability. The company is also building a proprietary pipeline to supplement it core business.

Continue reading Dr. Reddy's (RDY): Get ready for generic gains

Teva (TEVA): Generic profits

"Generic drug mak Teva Pharmaceutical, Ltd. (NASDAQ: TEVA) delivered respectable earnings results," says Jack Adamo, who added the stock his Insiders Plus model portfolio.

"The company's earnings were up 4% on a proforma non-GAAP basis. In this case, that's the correct measurement. Net GAAP earnings were up tremendously, but aren't really representative of normal business factors.

"Although Teva gets much of its earnings from its proprietary multiple sclerosis drug, Copaxone, its primary business is generic drugs. That segment is inherently lumpy because profitability is greatly affected by which generic drugs it brings to market before any other generic company.

Continue reading Teva (TEVA): Generic profits

Genomics: The next big thing?

"Genomics may be the 'next big thing' after the Internet and biotech. Finding those who can make money early onwill likely pay dividends to investors," expla]in small cap growth stock specialist Jim Oberweis, Jr.

In his The Oberweis Report, he explains the "politics" behind this bullish scenario as well as his top pick for log-term investors seeking exposure to the developing healthcare technologies if genomics and personalized medicine.

"We believe that the biotech boom was a direct consequence of rising National Health Institute (NIH) funding, cheap equity capital, and the ability to patent NIH-funded discoveries. And we see that happening again.

Continue reading Genomics: The next big thing?

Celgene (CELG): Selloff creates opportunity

"After warning that it would only achieve the low end of its previous guidance range for 2009, Celgene (NASDAQ: CELG) sold off significantly," notes biotech expert John McCamant.

Nevertheless, in his The Medical Technology Stock Letter he sees the selloff as any opportunity, calling the company a "great growth story."

"Celgene pre-announced 1Q 09 revenues of $600 million, which was significantly below Wall Street consensus estimates of $640-$650 million.

"The earnings miss was completely unexpected, and has partially shaken the belief that the Big Bios would be able to deliver solid earnings despite the economic problems.Nevertheless, we remain positive on the CELG story.

Continue reading Celgene (CELG): Selloff creates opportunity

Recession-proof stock #5: Johnson & Johnson (JNJ)

Recession stock: Johnson & JohnsonSome believe health care is the Holy Grail for investors in this horrible market, but I'm not so convinced.

When everyone jumps on a bandwagon, I usually like to jump off. It seems like everyone is preaching the merits of owning health care stocks. And when I say everyone, I mean everyone. Even the barber is touting this sector as a place to be during this recession and beyond. We shall see about that.

Instead of focusing on the space, how about looking at a specific name?

Continue reading Recession-proof stock #5: Johnson & Johnson (JNJ)

Healthcare favorites for long-term growth

"Long-time healthcare investors can be forgiven their confusion; drug stocks are supposed to be defensive, but many of the largest drugmakers have been pounded," observes Richard Moroney.

Nevertheless, in the blue chip Dow Theory Forecasts, the advisor sees two favorite healthcare and pharmaceutical issues as long-term opportunities: AstraZeneca (NYSE: AZN) and Johnson & Johnson (NYSE: JNJ).

Moroney explains, "Healthcare companies' profits are supposed to remain fairly steady regardless of the economic situation. But hospitals' capital spending fell in the December quarter, and many consumers are putting off medical care because they cannot afford it.

Continue reading Healthcare favorites for long-term growth

Immucor (BLUD): Two experts bank on blood bank buy

Two leading growth stock expert, Brandon Clay, editor of Invest with an Edge, and Alexander Green, editor of The Oxford Club, turn to automated blood testing equipment maker Immucor (NASDAQ: BLUD) as a recession-resistant buy.

Clay suggest, "A good bet is to go with the strongest stock in that particular sector at the time of your pickThat way, the company you select at least has the momentum of the sector backing it. Typically the medical industry performs better than the overall market in a downturn. This recession has been no different.

"As we dug deeper into health care, one company surfaced that was worth our attention. Immucor is a blood testing equipment manufacturer specializing in pre-transfusion diagnostics.

"Established in 1982, they brought their first patent to market four years later. Since then they've become a leader in blood diagnostics and blood bank technology.

Continue reading Immucor (BLUD): Two experts bank on blood bank buy

Ten stocks to fall in love with again: #8 Johnson & Johnson (JNJ)

Consumer health care companies are traditionally great recession plays, because no matter what happens in the economy, people still need their medicine.

For more than 100 years, Johnson & Johnson (NYSE: JNJ) has supplied the world with what it needs to ameliorate its ailments.

In addition to marquee consumer brands such as Band-Aid and Tylenol, Johnson & Johnson provides the world with a myriad of prescription drugs, medical devices and medical treatments that keep us all healthy.

The healing power -- and the earnings power -- of Johnson & Johnson's products has contributed to the well-being of both consumers and investors for a very long time.

And while shareholders may justifiably feel ill about the stock over the last several months, the company's long-term growth prospects will likely serve as a veritable love potion for investors in the years to come.

Take a look at all ten stocks to fall in love with again.

Jim Woods is a Senior Editor for OptionsZone.com.


Humana sputters, then hums

Humana (NYSE: HUM) reported earnings below analysts' expectations for the fourth quarter of 2008, spurring a quick sell-off of more than 3%.

The stock quickly recovered, due in part to the better-than-expected ISM report, and closed up almost 6% at $40.13.

Humana is one of the nations' largest providers of employer-based health care plans. Humana offers group health and dental plans for individuals and serves the health care needs of military families and seniors through a series of specialized plans.

The fourth-quarter earnings report disappointed analysts initially, as the report revealed a larger-than-expected decline in earnings of 28% from the previous year's fourth quarter.

Continue reading Humana sputters, then hums

Abbott (ABT): Contrarian sees healthy gains

"I think 2009 will be a very tough year for the economy but an exceptional year for stocks," says Alexander Green of The Oxford Club. Here, he looks at Abbott Laboratories (NYSE: ABT).

"The company has been around for more than 120 years. It currently operates in more than 130 countries, selling hundreds of products, including Ultane (an inhaled anesthetic), the anti-infective Biaxin XL, and TriCor and Niaspan to manage cholesterol.

"However, Abbott's biggest growth driver is Humira, a blockbuster drug that targets autoimmune disorders. The drug has received FDA approval to treat a number of diseases, including rheumatoid arthritis, psoriasis and Crohn's disease.

Continue reading Abbott (ABT): Contrarian sees healthy gains

Next Page >

Symbol Lookup
IndexesChangePrice
DJIA-139.7410,324.66
NASDAQ-27.492,148.56
S&P 500-15.691,094.94

Last updated: November 27, 2009: 11:44 AM

BloggingStocks Exclusives

Hot Stocks

DailyFinance Headlines

Latest from BloggingBuyouts

WalletPop Headlines

AOL Business News

BioHealth Investor Headlines

Sponsored Links

My Portfolios

Track your stocks here!

Find out why more people track their portfolios on AOL Money & Finance then anywhere else.

BloggingStocks Partners

More from AOL Money & Finance